Terms: = Germ cell tumor AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
53 results:
1. Molecular and clinicopathological implications of PRAME expression in adult glioma.
Le MK; Vuong HG; Dunn IF; Kondo T
PLoS One; 2023; 18(10):e0290542. PubMed ID: 37796789
[TBL] [Abstract] [Full Text] [Related]
2. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer.
Urbaniak A; Reed MR; Heflin B; Gaydos J; Piña-Oviedo S; Jędrzejczyk M; Klejborowska G; Stępczyńska N; Chambers TC; Tackett AJ; Rodriguez A; Huczyński A; Eoff RL; MacNicol AM
Biomed Pharmacother; 2022 Sep; 153():113440. PubMed ID: 36076555
[TBL] [Abstract] [Full Text] [Related]
3. MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/akt signaling.
Shen Q; Han Y; Wu K; He Y; Jiang X; Liu P; Xia C; Xiong Q; Liu R; Chen Q; Zhang Y; Zhao S; Yang C; Chen Y
Signal Transduct Target Ther; 2022 May; 7(1):147. PubMed ID: 35504869
[TBL] [Abstract] [Full Text] [Related]
4. CCL2 activates akt signaling to promote glycolysis and chemoresistance in glioma cells.
Qian Y; Ding P; Xu J; Nie X; Lu B
Cell Biol Int; 2022 May; 46(5):819-828. PubMed ID: 35178826
[TBL] [Abstract] [Full Text] [Related]
5. Silencing FYVE, RhoGEF, and PH domain containing 1 (FGD1) suppresses melanoma progression by inhibiting PI3K/akt signaling pathway.
Niu Z; Li Y; Xu Y; Jiang W; Tao R; Chen Y; Han Y
Bioengineered; 2021 Dec; 12(2):12193-12205. PubMed ID: 34783295
[TBL] [Abstract] [Full Text] [Related]
6. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract] [Full Text] [Related]
7. Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP cells and Maintains cell Survival.
Giordano F; Naimo GD; Nigro A; Romeo F; Paolì A; De Amicis F; Vivacqua A; Morelli C; Mauro L; Panno ML
Drug Des Devel Ther; 2019; 13():4265-4274. PubMed ID: 31908413
[TBL] [Abstract] [Full Text] [Related]
8. A Radiosensitivity Gene Signature and PD-L1 Status Predict clinical outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.
Jang BS; Kim IA
Cancer Res Treat; 2020 Apr; 52(2):530-542. PubMed ID: 31801317
[TBL] [Abstract] [Full Text] [Related]
9. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
10. Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Beclin-1-akt1 Complex Modulates Glioblastoma Therapy Sensitivity.
Vehlow A; Klapproth E; Jin S; Hannen R; Hauswald M; Bartsch JW; Nimsky C; Temme A; Leitinger B; Cordes N
Cell Rep; 2019 Mar; 26(13):3672-3683.e7. PubMed ID: 30917320
[TBL] [Abstract] [Full Text] [Related]
11. Distinct Molecular Profiles and Immunotherapy Treatment outcomes of V600E and V600K
Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
[TBL] [Abstract] [Full Text] [Related]
12. Loss of Phd2 cooperates with BRAF
Liu S; Zhang G; Guo J; Chen X; Lei J; Ze K; Dong L; Dai X; Gao Y; Song D; Ecker BL; Yang R; Feltcher C; Peng K; Feng C; Chen H; Lee RX; Kerestes H; Niu J; Kumar S; Xu W; Zhang J; Wei Z; Martin JS; Liu X; Mills G; Lu Y; Guo W; Sun L; Zhang L; Weeraratna A; Herlyn M; Wei W; Lee FS; Xu X
Nat Commun; 2018 Dec; 9(1):5426. PubMed ID: 30575721
[TBL] [Abstract] [Full Text] [Related]
13. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract] [Full Text] [Related]
14. Revisiting the clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract] [Full Text] [Related]
15. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.
Wu HB; Yang S; Weng HY; Chen Q; Zhao XL; Fu WJ; Niu Q; Ping YF; Wang JM; Zhang X; Yao XH; Bian XW
Autophagy; 2017 Sep; 13(9):1528-1542. PubMed ID: 28812437
[TBL] [Abstract] [Full Text] [Related]
16. Continuous Petri Nets and microRNA Analysis in Melanoma.
Russo G; Pennisi M; Boscarino R; Pappalardo F
IEEE/ACM Trans Comput Biol Bioinform; 2018; 15(5):1492-1499. PubMed ID: 28767374
[TBL] [Abstract] [Full Text] [Related]
17. TIAM1 variants improve clinical outcome in neuroblastoma.
Sanmartín E; Yáñez Y; Fornés-Ferrer V; Zugaza JL; Cañete A; Castel V; Font de Mora J
Oncotarget; 2017 Jul; 8(28):45286-45297. PubMed ID: 28423360
[TBL] [Abstract] [Full Text] [Related]
18. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/akt signaling in glioma.
Song Y; Zheng S; Wang J; Long H; Fang L; Wang G; Li Z; Que T; Liu Y; Li Y; Zhang X; Fang W; Qi S
Oncotarget; 2017 Jun; 8(26):41947-41962. PubMed ID: 28410212
[TBL] [Abstract] [Full Text] [Related]
19. Polymorphisms of insulin receptor substrate 2 are putative biomarkers for pediatric medulloblastoma: considering the genetic susceptibility and pathological diagnoses.
Baocheng W; Zhao Y; Meng W; Han Y; Wang J; Liu F; Qin S; Ma J
Nagoya J Med Sci; 2017 Feb; 79(1):47-54. PubMed ID: 28303061
[TBL] [Abstract] [Full Text] [Related]
20. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract] [Full Text] [Related]
[Next]
